Preclinical News and Research

RSS
Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Discovery Labs provides update on Surfaxin FDA marketing authorization for RDS in premature infants

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Advanced Targeting Systems awarded $3 million NCI grant to advance SP-SAP clinical program

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Sangamo completes enrollment in SB-509-901 Phase 2b clinical trial in diabetic neuropathy

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Oncolytics opens enrollment in REOLYSIN combination U.S. Phase I colorectal cancer study

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Takeda San Francisco and Pieris enter Anticalin scaffold technology collaboration

Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus

Positive preclinical results from Inovio's novel DNA vaccine targeting HIV Clade C virus

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

AMT enters agreement with Consortium for clinical development of novel gene therapy to treat Sanfilippo B

Researchers demystify death of brain cells in Parkinson's patients

Researchers demystify death of brain cells in Parkinson's patients

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

Intrexon Corporation, ZIOPHARM enter partnership to develop, commercialize DNA-based therapeutics

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

TD2 and Oncoholdings partner to accelerate development of superior oncology agents

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Generex, Antigen Express and RXi report positive research data from active immunotherapy collaboration

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

DARPA grants million dollar to IDRI to develop single dose influenza vaccine

DARPA grants million dollar to IDRI to develop single dose influenza vaccine

Receptos, Eli Lilly collaborate to develop molecule modulators of GPCR target

Receptos, Eli Lilly collaborate to develop molecule modulators of GPCR target

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Amgen, Xencor collaborate to develop XmAb5871 for autoimmune disease

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.